The appointment of an experienced oncology executive suggests the company is advancing its clinical programs, but investors should monitor pipeline progress and clinical trial results for tangible validation of this leadership change.
Price Chart
Executive Summary
Prelude Therapeutics appointed Dr. Charles Morris as Chief Medical Officer effective April 20, 2026. The appointment includes a $535,000 annual base salary and an equity grant of 450,000 stock options.
Key Facts
- Dr. Charles Morris appointed as Chief Medical Officer effective April 20, 2026
- Prior experience includes CMO roles at Lava Therapeutics, Celyad Oncology, and Radius Health
- Employment agreement includes $535,000 annual base salary
- 40% target bonus of base salary
- Option to purchase 450,000 shares of common stock
- Options vest 1/4th on one-year anniversary and monthly thereafter
Financial Impact
Compensation package includes $535,000 annual salary and equity grant of 450,000 options valued at approximately $24.5 million based on current market cap of $277M
Risk Factors
- High equity compensation could lead to significant shareholder dilution
- New CMO faces challenges in advancing clinical programs in competitive oncology space
- Company's market cap of $277M suggests limited financial resources compared to larger biotech firms
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-155978 |
| Document: prld-ex99_1.htm | 0001193125-26-155978 |
| Document: 0001193125-26-155978-index-headers.html | 0001193125-26-155978 |
| Document: 0001193125-26-155978-index.html | 0001193125-26-155978 |
| Document: 0001193125-26-155978.txt | 0001193125-26-155978 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 5w ago | Institutional Cluster | $4.85 $4.31 | ▼ −11.13% | ▼ −10.41% | $3.88 (−20.00%) |
Sep 10, 2026 6w ago | 8-K | $4.67 $4.59 | ▼ −1.71% | ▼ −2.57% | $3.88 (−16.92%) |
Sep 10, 2026 6w ago | Press Release | $4.67 $4.59 | ▼ −1.71% | ▼ −2.57% | $3.88 (−16.92%) |
Aug 11, 2026 11w ago | 8-K | $5.32 $5.73 | ▲ +7.71% | ▲ +7.46% | $3.88 (−27.07%) |
Aug 11, 2026 11w ago | Press Release | $5.32 $5.73 | ▲ +7.71% | ▲ +7.46% | $3.88 (−27.07%) |
May 12, 2026 24w ago | 8-K | $4.64 $4.66 | ▲ +0.43% | ▼ −0.14% | $3.88 (−16.38%) |
May 12, 2026 24w ago | Press Release | $4.64 $4.66 | ▲ +0.43% | ▼ −0.14% | $3.88 (−16.38%) |
Apr 28, 2026 26w ago | 3 | $4.27 $4.27 | · 0.00% | ▼ −1.02% | $3.88 (−9.13%) |
Apr 21, 2026 27w ago | Insider Cluster | $4.27 $5.23 | ▲ +22.48% | ▲ +21.46% | $3.88 (−9.13%) |
Apr 20, 2026 27w ago | 8-K | $4.51 $4.62 | ▲ +2.44% | ▲ +3.09% | $3.88 (−13.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers